As someone else noted, https://www.purposestudies.com/purpose1/ https://www.purposestudies.com/purpose1/ is the study page. Globally, women and adolescent girl

As someone else noted, https://www.purposestudies.com/purpose1/ https://www.purposestudies.com/purpose1/ is the study page. Globally, women and adolescent girls bear the highest burden of HIV, highlighting the critical need for effective HIV prevention options. In Sub-Saharan Africa, women and adolescent girls make up almost 60% of all new HIV infections. Stigma, marginalization, poverty, gender-based violence, and social inequities are some of the factors that have made women and adolescent girls especially vulnerable to HIV. PURPOSE 1, which enrolled cisgender women, will evaluate an investigational drug, lenacapavir, and an FDA-approved PrEP drug for people assigned male at birth, emtricitabine/ tenofovir alafenamide, also known as F/TAF or DESCOVY®, for PrEP. This trial is taking place in South Africa and Uganda and has completed enrollment.